Device Trial Radar · NCT07069556
ColoSense Post-Approval Study
Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12,500
Planned (sponsor's estimate)
Start
Sep 5, 2025
Primary completion
Sep 1, 2028
Study completion Sep 1, 2030
Sponsor
- Lead sponsor
- Geneoscopy, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 16, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of ColoSense.
Conditions
- Colorectal Cancer (Diagnosis)
Interventions
ColoSenseDevice
multi-target stool RNA test
Primary outcomes
What the sponsor says the trial is designed to measure.
- CRC SensitivityTime frame: Through study completion, an average of 5 years.
- AA SensitivityTime frame: Through study completion, an average of 5 years.
- SPL SensitivityTime frame: Through study completion, an average of 5 years.
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Decentralized Study
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.